SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Zuranolone 50 mg demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpointsZuranolone 50 mg was generally well-tolerated and demonstrated a safety profile consistent with prior studiesPostpa.
According to a study published in JAMA Network Open, a combination of in-person screenings and machine learning worked better than either method alone when it came to predicting suicide attempts and suicidal ideation in adults.